Trials / Recruiting
RecruitingNCT06553352
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
An Open, Single-Arm Clinical Study of Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma (FL)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.
Detailed description
Zanubrutinib (Z) 160mg bid oral d1-21 Obinutuzumab (O) C1 1000mg d1,8,15 C2-C6 d1 IV, then every 8 weeks until full 20 infusions (1 year maintenance)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib combined with Obinutuzumab | Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days. |
Timeline
- Start date
- 2024-03-31
- Primary completion
- 2026-04-20
- Completion
- 2027-08-31
- First posted
- 2024-08-14
- Last updated
- 2024-09-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06553352. Inclusion in this directory is not an endorsement.